Sutantatug envedotin

Antibody–drug conjugate

Also known as CRB-701

Phase 3planned

Evidence outlook · registrational

Cervical Cancer: registrational trial registered, not yet recruiting

No completed mid-stage readout is on record. Registrational readout expected around 2028-01-01.

Also in development:Urothelial Carcinoma · Phase 3

Featured evidence outside this drug's tracked markets:TEMPO-1 (NCT07768189) · Oropharyngeal Carcinoma (OPC) · Phase 3 · ungraded

Company guidance: data expected Q1 2027 (Corbus Pharmaceuticals, 10 Nov 2026). “Anticipate reporting sutantatug envedotin plus Keytruda® combination data in first-line (1L) OPSCC in Q1 2027 to support potential further registration-enabling trials in the 1L setting.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Cervical Cancer
Urothelial Carcinoma
Other / comorbidity
NCT07768189 · Corbus Pharmaceuticals Inc.
2026-09-29 – 2029-03 · Oropharyngeal Carcinoma (OPC)
What this study did
Phase 2 (2)
Urothelial Carcinoma
NCT07374549 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-20 – 2028-12-01 · Advanced Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06989671 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-08-30 – 2028-07-30 · Head and Neck Squamous Cell Carcinoma
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07241936 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-11-13 – 2028-10-30 · Advanced Solid Tumors
What this study did
NCT06265727 · Corbus Pharmaceuticals Inc.
2024-04-01 – 2027-01-27 · Solid Tumor, Adult
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sutantatug Envedotin: this drugPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Enfortumab Vedotin
Approved(overall)
Antibody–drug conjugateNectin-4
Partial signal(overall)
No reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
IPH4502
Phase 1(overall)
Antibody–drug conjugateNectin-4
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sutantatug envedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
January 2027 (1)
Phase 1/2Solid Tumor, AdultRecruiting
Est. primary completion 2027-01-16 · NCT06265727 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-10-30 · NCT07241936 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Oropharyngeal Carcinoma (OPC)Recruiting
Est. primary completion 2027-12 · NCT07768189 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT06989671 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 3Cervical CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07230626 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2028-06-01 · NCT07374549 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3Urothelial CarcinomaNot yet recruiting
Est. primary completion 2029-06-01 · NCT07526792 · CT.gov ↗
What to watch

See the full readout calendar ↗